Pharmaceutical Integrated Services: Key Attributes for Choosing the ...

As drug development gets ever more competitive, complex and costly, innovator and generic pharma companies are increasingly choosing contract development and manufacturing organizations (CDMOs) to streamline and significantly accelerate their pipelines. While there was a time when firms used to do all their R&D, manufacturing and commercial filing in-house, now they're looking to outsource those operations and leverage the proficiencies of CDMOs which provide end-to-end solutions.

Link to Lianhe Aigen

How can an integrated services program help your company achieve success?

Depending on a company's needs, a full-service CDMO can assist firms from start to finish in the drug development life cycle. CDMOs offer various services across the drug development pipeline from vital discovery research, supplying APIs, developing formulations to manufacturing and packaging. They can also help with technology transfers and regulatory clearances. Importantly, customers get access to the CDMO's specialist range of expertise. This, crucially, helps de-risk drug development, especially in the game-changing and scientifically challenging biotech area where the price of failure can be huge. CDMOs also offer customers the major convenience of having a one-person point-of-contact overseeing the entire project. In short, by putting many steps under one roof, CDMOs enable the process of bringing products to market more efficiently, safely and cost-effectively while meeting ever-tighter timelines.

What to seek in a CDMO? 

The CDMO segment is still highly fragmented, so choosing the best partner involves legwork. In scouting for the right fit, you want a CDMO which boasts of a project management team that can manage and execute all stages of the drug development and manufacturing process seamlessly. Such a set-up allows the customer to manage work not just sequentially but also in parallel across multiple sites to deliver quickly and efficiently. You also want your CDMO to have a scientifically and technically experienced team who have the expertise to come up with solutions to difficult problems and the ability to devise improved processes. In addition, vital to any successful corporate relationship is knowing that you'll be able to collaborate closely and communicate well with the CDMO throughout the entire project cycle. 

Got specialty needs for your molecules? Your CDMO must be able to address them.

Companies want a CDMO that can meet speciality needs such as high-potency active pharmaceutical ingredients (HAAPIs), highly-targeted Antibody Drug Conjugates (ADCs) and other complex molecules. It generally requires capital-intensive investments to have such capabilities in-house. To prevent delays, a CDMO should have a flexible supply chain with backward integration of APIs, Key Starting Materials and/or intermediates. For instance, when the Covid-19 pandemic erupted in Wuhan, it caused supply-chain issues related to raw materials sourced from China. (CDMOs have been reporting an up-tick in Covid-19-related outsourcing inquiries ever since the pandemic began).  

Global presence is a must.

Another CDMO attribute to check for is its global depth of offerings. If there are geopolitical issues in one area of the world, that impact supply having multiple sites allows the CDMO to conduct its work elsewhere in its network. This is a critical benefit, since the work CDMOs do for their sponsors has a direct impact on reducing the burden of disease on patients.

A successful track record speaks volumes.

Before committing to a partner, you'll want to rigorously examine the CDMO's track record to confirm that they've got the latest technology and are nimble and flexible in executing projects when circumstances suddenly change. Does the CDMO finish projects on time? Above all, you need a CDMO which has a robust regulatory compliance track record so your product does not get stuck anywhere along the ever more challenging journey to market. And ultimately, once a company finds the right CDMO to take ownership of their project, it has much more time to start bringing its next life-saving drug to market.

Kevin Duffield

Pharmaceutical Intermediates Market Size

Market Overview

Pharmaceutical Intermediates Market Analysis

The Pharmaceutical Intermediates Market size is estimated at USD 45.45 billion in , and is expected to reach USD 65.01 billion by , at a CAGR of 7.42% during the forecast period (-).

The pharmaceutical intermediates industry is experiencing significant transformation driven by increasing healthcare expenditure and infrastructure development globally. According to the Centers for Medicare & Medicaid Services (CMS) data published in March , United States healthcare spending increased substantially by 9.7% to reach USD 4.3 trillion in , compared to the 4.2% increase recorded in . This escalation in healthcare spending has created a robust foundation for pharmaceutical intermediates manufacturers. The growing emphasis on healthcare infrastructure development, particularly in emerging economies, has led to increased demand for pharmaceutical intermediates across various therapeutic applications.

The manufacturing landscape is witnessing substantial investments in capacity expansion and technological upgrades. In March , Sumitomo Chemical Co., Ltd announced plans to construct a new manufacturing plant for active pharmaceutical intermediates (APIs) and intermediates at its Oita Works in Japan, scheduled to commence operations in September . This facility aims to enhance the company's capability to supply high-quality APIs and intermediate pharmaceutical products for small molecule drugs. Similarly, in June , Vertellus acquired ESIM Chemicals' intermediates and specialties division to strengthen its position in serving pharmaceutical, coatings, fuel, and lubricant markets.

The industry is increasingly adopting advanced technologies to improve manufacturing efficiency and product quality. There has been a significant shift towards utilizing high-throughput screening, bioinformatics, and combinatorial chemistry for better drug candidate identification. The integration of artificial intelligence in drug discovery and development processes has emerged as a transformative trend, enabling faster and more cost-effective development of pharma intermediates. These technological advancements are particularly crucial as the World Health Organization reports that Chronic Obstructive Pulmonary Disease (COPD) remains the third most common cause of morbidity and mortality globally as of January .

The market is experiencing a strategic shift in supply chain dynamics and regulatory compliance measures. Governments across various regions are implementing initiatives to strengthen domestic pharmaceutical intermediate companies. For instance, the Indian government's approval of bulk pharmaceutical intermediates parks in multiple states demonstrates the growing focus on reducing import dependencies and establishing robust local supply chains. This shift is accompanied by stringent quality control measures and regulatory frameworks, ensuring the production of high-quality intermediate products in the pharmaceutical industry while maintaining environmental sustainability standards.

Pharmaceutical Intermediates Market Trends

Increasing Prevalence of Chronic Diseases

The rising burden of chronic diseases worldwide has become a significant driver for the pharmaceutical intermediates market, particularly in cardiovascular diseases. According to recent studies published in the Cureus Journal of Medical Science, approximately 126 million people globally (1.72% of the world's population) are affected by ischemic heart disease, with projections indicating an increase to 1,845 cases per 100,000 people worldwide by . This growing prevalence creates substantial demand for pharmaceutical intermediates used in manufacturing cardiovascular medications and related treatments.

The impact of lifestyle factors and behavioral patterns has further contributed to the rising incidence of chronic diseases. For instance, in France, recent data from World Population Review () indicates that 11.10% of men and 3.10% of women are affected by alcoholism, a significant risk factor for heart disease. Similarly, the British Heart Foundation's UK Factsheet reveals that 7.6 million people in the United Kingdom are affected by heart and circulation disorders, with these conditions accounting for more than 160,000 deaths annually—representing 25% of all deaths in the country. This substantial disease burden necessitates increased production of bulk drug intermediates to support the manufacturing of various therapeutic medications.

Understand The Key Trends Shaping This Market Download PDF

Growing R&D Initiatives and Activities in the Pharmaceutical Industry

The pharmaceutical industry has witnessed significant growth in research and development initiatives, supported by substantial public funding and institutional backing. The National Institutes of Health (NIH) has received more than USD 700 billion in public funding over recent decades, demonstrating a strong commitment to advancing pharmaceutical research and development. This investment has directly contributed to the expansion of clinical trials and drug development programs, which require various pharma intermediates throughout the research and manufacturing processes.

The scale of research activities is evidenced by the extensive number of clinical trials being conducted, with 443,207 registered clinical studies in the United States as of November . Of particular significance, 1,397 studies have reached Phase III clinical trials with FDA or EMA approval, spanning diverse therapeutic areas. This robust pipeline of drug development creates sustained demand for drug intermediates, as each new drug candidate requires specific intermediate compounds during its development and manufacturing phases. Additionally, the focus on treating infectious diseases has intensified, as demonstrated by CDC statistics showing 7,174 tuberculosis cases in the United States (2.2 per 100,000 people) and approximately 1.35 million Salmonella infections annually, further driving the need for intermediate drugs in developing new treatments.

Segment Analysis: By Type

Bulk Drug Intermediates Segment in Pharmaceutical Intermediates Market

The bulk drug intermediates segment continues to dominate the pharmaceutical intermediates market, holding approximately 49% market share in . This significant market position is attributed to the segment's crucial role in producing active pharmaceutical ingredients (APIs) and raw materials for bulk drugs. The segment's strength is further reinforced by increasing government initiatives worldwide to promote domestic bulk drug production and reduce dependency on imports. For instance, several countries have established dedicated bulk drug parks and implemented favorable policies to boost local manufacturing capabilities. The segment encompasses both chiral and achiral intermediates, with key products including Beta-Chloroalanine HCL, N-Phthaloyl L-Glutamic acid, and (S)-α-Amino-γ-butyrolactone.HCl, which are essential components in various pharmaceutical manufacturing processes.

Chemical Intermediates Segment in Pharmaceutical Intermediates Market

The chemical intermediates segment is projected to exhibit the highest growth rate of approximately 8% during the forecast period -. This accelerated growth is driven by increasing demand for specialty chemicals and advanced chemical intermediate market in pharmaceutical manufacturing. The segment's expansion is supported by strategic initiatives from market players, including significant investments in research and development for novel intermediate compounds. The growth is further bolstered by the rising adoption of advanced technologies in pharmaceutical manufacturing processes and the increasing complexity of drug development requiring specialized chemical intermediates. Additionally, the segment benefits from the growing trend of outsourcing developmental and manufacturing facilities, particularly in emerging markets.

Remaining Segments in Pharmaceutical Intermediates Market by Type

The custom intermediates segment plays a vital role in the pharmaceutical intermediates market by providing specialized solutions for specific company requirements. This segment focuses on exclusive manufacturing of intermediates on defined scales, typically under confidentiality agreements and strict deadlines. Custom intermediates are particularly crucial for pharmaceutical companies developing novel drugs or requiring unique molecular structures. The segment's significance is enhanced by its ability to provide tailored solutions ranging from milligram to kilogram scales, supporting both research and commercial production phases of drug development. The flexibility and specialized nature of custom intermediates make them indispensable in the pharmaceutical manufacturing landscape.

Segment Analysis: By Application

Cardiovascular Drugs Segment in Pharmaceutical Intermediates Market

The cardiovascular drugs segment continues to dominate the pharmaceutical intermediates market, holding approximately 41% market share in . This significant market position is driven by the increasing global burden of cardiovascular diseases and the growing elderly population worldwide. The segment's prominence is further strengthened by the extensive use of intermediates in manufacturing various cardiovascular medications, including antihypertensive drugs, anticoagulants, and cholesterol-lowering medications. Major pharmaceutical companies are increasingly focusing on developing novel cardiovascular drugs, which has led to heightened demand for specialized intermediates in this segment.

Oral Anti-diabetic Drugs Segment in Pharmaceutical Intermediates Market

The oral anti-diabetic drugs segment is emerging as the fastest-growing segment in the pharmaceutical intermediates market, projected to grow at approximately 8% during -. This remarkable growth is primarily attributed to the rising global prevalence of diabetes and increasing adoption of oral medications over injectable treatments. The segment's growth is further fueled by ongoing research and development activities focused on developing new and more effective oral anti-diabetic medications. Pharmaceutical companies are investing heavily in innovative drug formulations, creating a robust demand for specialized intermediate pharmaceutical products used in the manufacturing of these medications.

Remaining Segments in Application Segmentation

The pharmaceutical intermediates market also encompasses other significant segments including anti-infective and anti-microbial drugs, analgesics, and various other therapeutic applications. The anti-infective and anti-microbial segment maintains a strong presence due to the continuous need for new antibiotics and antiviral medications. The analgesics segment plays a crucial role in pain management medications, while other applications cover a diverse range of therapeutic areas including neurological disorders, respiratory conditions, and gastrointestinal treatments. These segments collectively contribute to the market's diversity and demonstrate the widespread application of pharmaceutical formulation intermediates across different therapeutic areas.

Segment Analysis: By End Users

Biotech and Pharma Companies Segment in Pharmaceutical Intermediates Market

The Biotech and Pharma Companies segment dominates the global pharmaceutical intermediates market, commanding approximately 81% of the total market share in . This segment's prominence is driven by the increasing focus on research and development activities by pharmaceutical and biotechnology companies worldwide. The strategic initiatives and supply agreements between market players have significantly contributed to this segment's dominance. For instance, major pharmaceutical companies are actively expanding their manufacturing capacities for APIs and intermediates to meet the growing demand for small molecule drugs. The segment's leadership position is further strengthened by the increasing number of drug approvals by regulatory authorities, creating sustained demand for pharmaceutical intermediates. Additionally, this segment is experiencing the highest growth rate of around 7% for the forecast period -, driven by increasing investments in research and development, expanding manufacturing capabilities, and rising demand for novel drug formulations.

Research Institutes Segment in Pharmaceutical Intermediates Market

The Research Institutes segment plays a crucial role in advancing pharmaceutical intermediate development through academic and institutional research. This segment is characterized by extensive collaboration between pharmaceutical companies and research institutes, supported by government funding and grants. Research institutes are increasingly focusing on developing innovative drug discovery processes and novel pharmaceutical intermediates, contributing to the advancement of the pharmaceutical industry. The segment's growth is driven by rising investments in drug research, increasing number of clinical trials, and growing partnerships between academic institutions and pharmaceutical companies. Research institutes are also playing a vital role in developing more efficient and sustainable production methods for pharmaceutical intermediates, which is essential for the future of drug development. The collaboration between research institutes and pharmaceutical companies has led to significant breakthroughs in drug development processes, creating new opportunities for pharmaceutical intermediate applications.

Remaining Segments in End Users Market

The Other End Users segment, which includes contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), represents a significant portion of the pharmaceutical intermediates market. These organizations provide crucial support services to the pharmaceutical industry through outsourced pharmaceutical research and manufacturing capabilities. CDMOs particularly play a vital role by offering comprehensive services from drug development through manufacture, while CROs support drug manufacturers in discovery and approval processes. The growing trend of outsourcing developmental and manufacturing facilities has strengthened this segment's position in the market. These organizations are increasingly investing in expanding their capabilities and adopting advanced technologies to meet the evolving needs of the pharmaceutical industry, making them an integral part of the pharmaceutical intermediates supply chain.

Pharmaceutical Intermediates Market Geography Segment Analysis

Pharmaceutical Intermediates Market in North America

The North American pharmaceutical intermediates market demonstrates robust growth driven by advanced research facilities, an increasing prevalence of chronic diseases, and substantial healthcare investments. The United States leads the regional intermediate market, followed by Canada and Mexico. The region benefits from the presence of major pharmaceutical intermediates manufacturers, a well-established healthcare infrastructure, and increasing government support for pharmaceutical research and development activities. The regulatory framework in North America, particularly the FDA guidelines in the United States, plays a crucial role in shaping the market dynamics and ensuring quality standards in pharmaceutical intermediates production.

Pharmaceutical Intermediates Market in the United States

The United States dominates the North American pharmaceutical intermediates market, holding approximately 92% of the regional market share. The country's market leadership is attributed to its advanced research and development facilities, robust pharmaceutical manufacturing sector, and increasing prevalence of various chronic conditions. The presence of major pharmaceutical intermediate companies, coupled with significant investments in healthcare research, drives market growth. The country's healthcare system supports extensive clinical trials and drug development programs, while the FDA's regulatory framework ensures high-quality standards in pharmaceutical intermediates production. The United States also benefits from a strong network of pharmaceutical intermediates suppliers, contributing to its market dominance.

Pharmaceutical Intermediates Market in Canada

Canada emerges as the fastest-growing market in North America, with a projected CAGR of approximately 8% during -. The country's pharmaceutical intermediates market is experiencing rapid expansion due to increasing private and public investment in research and development activities. Canada's robust manufacturing sector, particularly in Ontario and Quebec, serves as economic centers for pharmaceutical production. The country's strategic focus on healthcare innovation, coupled with government initiatives to support pharmaceutical research, drives market growth. The presence of well-established research institutions and increasing collaboration between academic and industrial sectors further strengthens Canada's position in the pharmaceutical intermediates market.

Pharmaceutical Intermediates Market in Europe

The European pharmaceutical intermediates market showcases significant growth potential, supported by a well-established pharmaceutical manufacturing infrastructure and strong research capabilities. The region encompasses key markets including Germany, the United Kingdom, France, Italy, and Spain, each contributing significantly to the overall market landscape. Europe's market is characterized by stringent quality standards, advanced manufacturing capabilities, and substantial investments in pharmaceutical research and development. The presence of major pharmaceutical companies and research institutions across these countries further strengthens the regional market dynamics.

Pharmaceutical Intermediates Market in Germany

Germany leads the European pharmaceutical intermediates market, commanding approximately 20% of the regional market share. The country's dominance is attributed to its well-organized healthcare system, robust pharmaceutical manufacturing base, and significant investments in research and development. Germany's pharmaceutical sector benefits from advanced manufacturing capabilities, a strong regulatory framework, and the presence of major pharmaceutical companies. The country's commitment to healthcare innovation and quality standards in pharmaceutical production maintains its position as a key player in the European market.

Are you interested in learning more about Intermediates Pharma Service? Contact us today to secure an expert consultation!

Pharmaceutical Intermediates Market in the United Kingdom

The United Kingdom demonstrates the highest growth potential in the European region, with an expected CAGR of approximately 8% during -. The country's pharmaceutical intermediates market benefits from significant government investments in research and development, the presence of major pharmaceutical companies, and a strong focus on healthcare innovation. The UK's market is supported by well-established research institutions, advanced manufacturing facilities, and an increasing focus on developing novel pharmaceutical products. The country's strategic initiatives to strengthen its pharmaceutical manufacturing capabilities and research infrastructure contribute to its rapid market growth.

Pharmaceutical Intermediates Market in Asia-Pacific

The Asia-Pacific pharmaceutical intermediates market demonstrates dynamic growth potential, encompassing diverse markets including China, Japan, India, Australia, and South Korea. The region benefits from increasing investments in pharmaceutical manufacturing, growing healthcare infrastructure, and rising demand for pharmaceutical products. The market is characterized by the presence of both established pharmaceutical intermediates manufacturers and emerging players, creating a competitive landscape that drives innovation and market expansion.

Pharmaceutical Intermediates Market in China

China maintains its position as the largest market for pharmaceutical intermediates in the Asia-Pacific region. The country's dominance is attributed to its extensive manufacturing capabilities, large-scale production facilities, and significant role in the global pharmaceutical supply chain. China's pharmaceutical sector benefits from government support, increasing investments in research and development, and the presence of numerous pharmaceutical manufacturers. The country's strategic focus on becoming a global pharmaceutical manufacturing hub further strengthens its market position.

Pharmaceutical Intermediates Market in India

India emerges as the fastest-growing market in the Asia-Pacific region for pharmaceutical intermediates. The country's market growth is driven by its strong manufacturing capabilities, increasing focus on research and development, and government initiatives to promote domestic pharmaceutical production. India's pharmaceutical sector benefits from a skilled workforce, cost-effective manufacturing processes, and growing exports of pharmaceutical products. The country's emphasis on becoming self-reliant in pharmaceutical production and its position as a major supplier of generic drugs contribute to its rapid market expansion.

Pharmaceutical Intermediates Market in Middle East & Africa

The Middle East & Africa pharmaceutical intermediates market shows steady growth potential, with key markets including GCC countries and South Africa. The region's market is characterized by increasing investments in healthcare infrastructure, growing pharmaceutical manufacturing capabilities, and rising demand for pharmaceutical products. Within the region, GCC countries emerge as the largest market, while South Africa demonstrates the fastest growth potential. The market benefits from government initiatives to strengthen domestic pharmaceutical production and increasing healthcare expenditure across the region.

Pharmaceutical Intermediates Market in South America

The South American pharmaceutical intermediates market exhibits promising growth prospects, with Brazil and Argentina serving as key markets in the region. The market is driven by increasing healthcare investments, growing pharmaceutical manufacturing capabilities, and rising demand for pharmaceutical products. Brazil emerges as the largest market in the region, while Argentina shows the fastest growth potential. The region's market benefits from improving healthcare infrastructure, government support for pharmaceutical production, and an increasing presence of both domestic and international pharmaceutical manufacturers.

Get Analysis on Important Geographic Markets Download PDF

Pharmaceutical Intermediates Industry Overview

Top Companies in Pharmaceutical Intermediates Market

The pharmaceutical intermediates market is characterized by companies focusing on expanding their manufacturing capabilities and enhancing their product portfolios through strategic initiatives. Market leaders are investing heavily in research and development to develop innovative intermediates for novel drug formulations while simultaneously strengthening their distribution networks across regions. Companies are increasingly adopting sustainable manufacturing practices and green chemistry principles in their production processes to meet environmental regulations and customer demands. The industry is witnessing a trend towards vertical integration, with pharmaceutical intermediates manufacturers establishing in-house manufacturing facilities for key intermediates to ensure supply chain security. Additionally, market players are forming strategic partnerships and collaborations to leverage technological expertise and expand their geographical presence, particularly in emerging markets with growing pharmaceutical manufacturing bases.

Fragmented Market with Strong Regional Players

The pharmaceutical intermediates market exhibits a fragmented structure with a mix of global chemical conglomerates and specialized regional manufacturers. Large multinational companies, particularly from developed regions, dominate the high-end intermediate segments requiring complex manufacturing processes and stringent quality controls. These established players leverage their extensive R&D capabilities, advanced manufacturing facilities, and global distribution networks to maintain their market positions. Regional players, especially from emerging economies, are gaining prominence in the basic and medium-complexity intermediates segment by offering cost-competitive products and maintaining close relationships with local pharmaceutical manufacturers.

The market is witnessing increased consolidation through mergers and acquisitions, as companies seek to expand their product portfolios and strengthen their market presence. Major chemical companies are acquiring specialized intermediate manufacturers to gain access to proprietary technologies and established customer relationships. Simultaneously, regional players are forming joint ventures with global companies to enhance their technological capabilities and expand their market reach. This consolidation trend is particularly evident in regions with strong pharmaceutical manufacturing bases, where companies are looking to establish integrated production facilities.

Innovation and Compliance Drive Market Success

Success in the pharma intermediates market increasingly depends on companies' ability to develop innovative products while maintaining strict quality standards and regulatory compliance. Market leaders are investing in advanced manufacturing technologies and automation to improve production efficiency and ensure consistent product quality. Companies are also focusing on developing green chemistry solutions and sustainable manufacturing processes to meet growing environmental regulations and customer preferences. Building strong relationships with pharmaceutical intermediate suppliers through reliable supply chains and technical support services has become crucial for maintaining market share.

For new entrants and smaller players, specialization in niche intermediate segments and focus on regional markets present viable growth strategies. Companies can gain a competitive advantage by developing expertise in specific chemical processes or targeting emerging therapeutic areas with growing intermediate demands. Regulatory compliance and quality certifications have become essential success factors, as pharmaceutical manufacturers increasingly prioritize suppliers with strong track records in meeting international standards. The ability to adapt to changing market dynamics, including shifts in drug development trends and evolving regulatory requirements, will be crucial for long-term success in this market.

Pharmaceutical Intermediates Market Leaders

1. Chiracon GmbH

2. BASF SE

3. Sanofi SAIS

4. Aceto

5. Codexis, Inc.

6. *Disclaimer: Major Players sorted in no particular order

Need More Details on Market Players and Competitors? Download PDF

Pharmaceutical Intermediates Market News

• In March , Sumitomo Chemical Co., Ltd. announced that it will construct a new manufacturing plant for active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan). This project is to enhance the Company's capacity to supply a variety of high-quality APIs and intermediates in response to the increasing demand for small-molecule drugs.
• In October , AstraZeneca's Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
• In February , three manufacturing facilities have been purchased by CordenPharma from Vifor Pharma. These facilities will eventually be renamed Corden Pharma Fribourg S.A. in Switzerland (with its branch in Ettingen) and Corden Pharma Lisbon S.A. in Portugal.

Pharmaceutical Intermediates Market Report - Table of Contents

1. INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence of Chronic Diseases
  • 4.2.2 Growing R&D Initiatives and Activities in the Pharmaceutical Industry
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Issues Regarding Certain Pharmaceutical Intermediate Substances
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

• 5.1 By Type
  • 5.1.1 Chemical Intermediate
  • 5.1.2 Bulk Drug Intermediate
  • 5.1.3 Others
• 5.2 By Application
  • 5.2.1 Analgesics
  • 5.2.2 Anti-Infective Drugs
  • 5.2.3 Cardiovascular Drugs
  • 5.2.4 Oral Antidiabetic Drugs
  • 5.2.5 Antimicrobial Drugs
  • 5.2.6 Others
• 5.3 By End-User
  • 5.3.1 Biotech and Pharma Companies
  • 5.3.2 Research Institutions
  • 5.3.3 Others
• 5.4 Geography
  • 5.4.1 North America
  • 5.4.1.1 United States
  • 5.4.1.2 Canada
  • 5.4.1.3 Mexico
  • 5.4.2 Europe
  • 5.4.2.1 Germany
  • 5.4.2.2 United Kingdom
  • 5.4.2.3 France
  • 5.4.2.4 Italy
  • 5.4.2.5 Spain
  • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
  • 5.4.3.1 China
  • 5.4.3.2 Japan
  • 5.4.3.3 India
  • 5.4.3.4 Australia
  • 5.4.3.5 South Korea
  • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
  • 5.4.4.1 GCC
  • 5.4.4.2 South Africa
  • 5.4.4.3 Rest of Middle-East and Africa
  • 5.4.5 South America
  • 5.4.5.1 Brazil
  • 5.4.5.2 Argentina
  • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 A.R. Life Science
  • 6.1.2 Aceto Corporation
  • 6.1.3 BASF SE
  • 6.1.4 Chiracon GmbH
  • 6.1.5 Codexis, Inc.
  • 6.1.6 Dishman Group
  • 6.1.7 Green Vision Life Sciences
  • 6.1.8 Lianhetech
  • 6.1.9 Midas Pharma GmbH
  • 6.1.10 Sanofi SAIS
  • 6.1.11 Vertellus Holdings LLC
  • 6.1.12 Yin-sheng Bio-tech Co., Ltd.
• *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections Get Price Break-up Now

Pharmaceutical Intermediates Industry Segmentation

As per the scope of the report, pharmaceutical intermediates are the drugs used as raw materials for the production of bulk drugs, or they can refer to a material produced during the synthesis of an API that must undergo further molecular change or processing before it becomes an API. The Pharmaceutical Intermediates Market is Segmented by Type (Chemical Intermediate, Bulk Drug Intermediate, and Others), Application (Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, and Others), End-User (Biotech and Pharma Companies, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Type Chemical Intermediate Bulk Drug Intermediate Others By Application Analgesics Anti-Infective Drugs Cardiovascular Drugs Oral Antidiabetic Drugs Antimicrobial Drugs Others By End-User Biotech and Pharma Companies Research Institutions Others Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific Middle-East and Africa GCC South Africa Rest of Middle-East and Africa South America Brazil Argentina Rest of South America By Type Chemical Intermediate Bulk Drug Intermediate Others By Application Analgesics Anti-Infective Drugs Cardiovascular Drugs Oral Antidiabetic Drugs Antimicrobial Drugs Others By End-User Biotech and Pharma Companies Research Institutions Others Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific Middle-East and Africa GCC South Africa Rest of Middle-East and Africa South America Brazil Argentina Rest of South America Need A Different Region or Segment? Customize Now

Pharmaceutical Intermediates Market Research FAQs

How big is the Pharmaceutical Intermediates Market?

The Pharmaceutical Intermediates Market size is expected to reach USD 45.45 billion in and grow at a CAGR of 7.42% to reach USD 65.01 billion by .

What is the current Pharmaceutical Intermediates Market size?

In , the Pharmaceutical Intermediates Market size is expected to reach USD 45.45 billion.

Who are the key players in Pharmaceutical Intermediates Market?

Chiracon GmbH, BASF SE, Sanofi SAIS, Aceto and Codexis, Inc. are the major companies operating in the Pharmaceutical Intermediates Market.

Which is the fastest growing region in Pharmaceutical Intermediates Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (-).

Which region has the biggest share in Pharmaceutical Intermediates Market?

In , the North America accounts for the largest market share in Pharmaceutical Intermediates Market.

What years does this Pharmaceutical Intermediates Market cover, and what was the market size in ?

In , the Pharmaceutical Intermediates Market size was estimated at USD 42.08 billion. The report covers the Pharmaceutical Intermediates Market historical market size for years: , , and . The report also forecasts the Pharmaceutical Intermediates Market size for years: , , , , and .

If you want to learn more, please visit our website ADC Linker Pharma Service.